Skeletal muscle physiology

Intuition [Beginner]

When you flex your arm, a molecular engine inside each muscle fibre is at work. Skeletal muscle is built from long, cylindrical cells called muscle fibres. Each fibre is packed with smaller units called myofibrils, and each myofibril is divided into repeating segments called sarcomeres — the basic contractile units.

A sarcomere runs from one Z-line to the next. In between lie two kinds of protein filaments: thick filaments made of myosin and thin filaments made primarily of actin. Under a microscope, the overlapping pattern of these filaments produces the striped (striated) appearance of skeletal muscle.

The key idea of the sliding filament theory is that the filaments themselves do not shorten. Instead, the thin filaments slide past the thick filaments, pulling the Z-lines closer together. This sliding is driven by molecular "oars" — the myosin heads — that grab actin, pull, release, and grab again in a cycle powered by ATP. Each cycle shortens the sarcomere by a tiny amount; millions of sarcomeres shortening in parallel produce the visible contraction of the whole muscle.

A single sarcomere at rest is about 2.4 micrometres long. During maximal contraction, it can shorten to about 1.8 micrometres — a 25% reduction in length. The force a sarcomere produces depends on how much the filaments overlap: too much or too little overlap reduces force.

Visual [Beginner]

The sarcomere can be drawn as a set of overlapping rods. The thick (myosin) filaments form a central band called the A-band, which stays the same length during contraction. The thin (actin) filaments extend from the Z-lines at each end.

As the sarcomere shortens, the thin filaments slide inward, increasing their overlap with the thick filaments. The light-coloured I-band (thin filament only, no overlap) narrows. The central H-zone (thick filament only, no overlap) also narrows and may disappear at full contraction.

The length-tension curve plots sarcomere force against sarcomere length. Maximum force occurs at the resting length (~2.0-2.2 micrometres) where overlap is optimal. Force decreases at longer lengths (too little overlap) and at shorter lengths (filaments crumple into each other).

Worked example [Beginner]

A sarcomere shortens from 2.4 micrometres to 1.8 micrometres during contraction. Calculate the percentage shortening.

Step 1. Find the change in length:

$$\Delta L=2.4-1.8=0.6\text{ mum}.$$

Step 2. Divide by the original length and multiply by 100:

$$\text{Percentage shortening}=\frac{0.6}{2.4}\times 100=25\%.$$

A 25% shortening at the sarcomere level translates to the same percentage shortening at the whole-muscle level, because sarcomeres are arranged in series along the myofibril.

Check your understanding [Beginner]

Formal definition [Intermediate+]

A sarcomere is bounded by two adjacent Z-lines and contains the following structural elements:

• Thick filaments: myosin II molecules, each ~1.6 $\mu$m long, centred at the M-line. Each myosin molecule has a globular head domain that contains ATPase activity and binding sites for actin.
• Thin filaments: actin polymers ~1.0 $\mu$m long, anchored at the Z-line, extending toward the centre. Associated regulatory proteins are tropomyosin (a coiled-coil that blocks myosin binding sites on actin in the resting state) and troponin (a complex of TnC, TnI, and TnT that senses calcium and moves tropomyosin).

Excitation-contraction coupling describes the sequence from action potential to force generation:

1. An action potential arrives at the neuromuscular junction and depolarises the muscle fibre membrane.
2. Depolarisation spreads along the transverse tubule (T-tubule) system into the fibre interior.
3. The dihydropyridine receptor (DHPR) in the T-tubule membrane mechanically couples to the ryanodine receptor (RyR1) on the sarcoplasmic reticulum, triggering calcium release.
4. Calcium binds troponin C, causing tropomyosin to shift and expose myosin-binding sites on actin.
5. Myosin heads perform the cross-bridge cycle: bind actin, power stroke (release of ADP and Pi), detach (ATP binding), and re-cock (ATP hydrolysis).
6. Calcium is pumped back into the sarcoplasmic reticulum by the SERCA pump (consuming ATP), allowing relaxation.

Isometric contraction produces force without length change (the muscle is held at fixed length). Isotonic contraction produces length change against a constant load. The two conditions generate different force-velocity relationships.

The Hill equation

A. V. Hill (1938) showed that the relationship between muscle force $F$ and shortening velocity $v$ during isotonic contraction is hyperbolic:

$$(F+a)(v+b)=(F_0+a)b=\text{constant},$$

where $F_0$ is the maximum isometric force and $a$, $b$ are constants with dimensions of force and velocity respectively. At zero load ($F=0$), shortening velocity is maximal ($v=v_{\max }=F_{0}b/a$). At zero velocity ($v=0$), force equals $F_0$.

Twitch, summation, and tetanus

A single action potential produces a twitch — a brief contraction lasting 20-100 ms depending on fibre type. If a second stimulus arrives before the first twitch has fully relaxed, the second twitch adds to the residual force of the first (summation). At sufficiently high stimulation frequencies, individual twitches fuse into a sustained contraction called tetanus, producing maximum force that may be 3-4 times the single-twitch amplitude.

Fibre types

Skeletal muscle fibres are classified by their contractile and metabolic properties:

• Type I (slow-twitch, oxidative): high mitochondrial density, high capillary supply, fatigue-resistant, low $v_{\max }$, red appearance (myoglobin-rich). Specialised for endurance.
• Type IIa (fast-twitch, oxidative-glycolytic): intermediate properties, moderately fatigue-resistant.
• Type IIx/IIb (fast-twitch, glycolytic): low mitochondrial density, low capillary supply, fast fatigue, high $v_{\max }$, white appearance. Specialised for brief, powerful bursts.

Key theorem with proof [Intermediate+]

Theorem (Length-tension relationship). The active force generated by a sarcomere is proportional to the number of actin-myosin cross-bridges that can form, which is a function of sarcomere length. Maximum active force occurs at the optimal sarcomere length $L_0$ (~2.0-2.2 $\mu$m) where overlap between thick and thin filaments is maximal without interference. Active force decreases linearly at lengths above and below $L_0$ due to reduced overlap and filament interference, respectively.

Proof. Consider a sarcomere with thick filament length $L_M$ (1.6 $\mu$m) and thin filament length (from each Z-line) $L_A$ (1.0 $\mu$m). The half-sarcomere overlap region determines the number of available cross-bridge sites.

At optimal length $L_0$: all myosin heads within the A-band have access to actin binding sites. Cross-bridge count is maximal and so is force.

For lengths $L>L_0$: the overlap decreases as thin filaments are pulled outward. Active force decreases linearly with the reduction in overlap, reaching zero when the filaments no longer overlap at all ($L>L_M+2L_A\approx 3.6\text{ mum}$).

For lengths $L<L_0$: thin filaments from opposite Z-lines begin to overlap at the centre, and thick filaments collide with the Z-line. The resulting interference disrupts cross-bridge formation, and active force again decreases. Below approximately 1.6 $\mu$m, force approaches zero. $\square$

This relationship was demonstrated by Gordon, Huxley, and Julian (1966) in single frog muscle fibres held at precisely controlled sarcomere lengths. It remains one of the most elegant structure-function demonstrations in all of physiology.

Exercises [Intermediate+]

Fibre types and the metabolic-mechanical spectrum [Master]

The mature mammalian skeletal muscle fibre population is not a homogeneous tissue but a continuous spectrum of contractile-and-metabolic phenotypes pinned by three discrete states. The molecular substrate of cross-bridge cycling is treated at the system level here; the actin-myosin biophysics is the subject of 18.04.02 pending and is taken as a given for the fibre-level integration.

The myosin heavy-chain (MyHC) isoform decision. The single sharpest classifier of mammalian skeletal muscle fibres is the heavy-chain isoform expressed by their thick filaments. Four MyHC isoforms exist in adult limb muscle: MyHC-I (slow), MyHC-IIa, MyHC-IIx, and MyHC-IIb (the last absent in larger mammals including humans, where IIx is the fastest). The isoforms differ in their ATPase rate by roughly a factor of three between MyHC-I and MyHC-IIx, with corresponding differences in unloaded shortening velocity. Schiaffino and Reggiani's 2011 Physiol. Rev. synthesis catalogues the isoform-by-isoform mechanical parameters and remains the canonical reference. The genes (MYH7 for slow, MYH2/MYH1/MYH4 for IIa/IIx/IIb) are clustered and expressed under coordinated control; a single fibre is in principle pure-isoform but in practice many fibres co-express two adjacent isoforms, generating a continuum of hybrid phenotypes (I/IIa, IIa/IIx) that lies on the slow-to-fast axis.

The metabolic phenotype tracks the mechanical one. Type I fibres have high mitochondrial volume density (10-15% of cell volume in human soleus versus 2-4% in vastus lateralis IIx-rich fibres), dense capillary supply (4-5 capillaries per fibre versus 2-3 in fast fibres), elevated myoglobin (giving the red appearance), and elevated activity of the oxidative-phosphorylation enzyme complexes. Their bioenergetic chain is treated at the molecular level in 17.04.02 pending oxidative phosphorylation, and the glycolytic side that dominates fast-fibre metabolism is in 17.04.01 glycolysis and the citric-acid cycle; here we read those chemistries as the supply side of an ATP-supply-demand balance whose demand side is the cross-bridge cycle rate of 18.04.02 pending. The supply-demand calculus is the central organising fact of fibre-type physiology: a fibre can be fast OR efficient, not both, because the ATP delivery rate of mitochondria has a hard ceiling set by the partial pressure of oxygen, the capillary delivery rate, and the mitochondrial volume fraction.

Fatigue physiology and the fast-fibre trade-off. When a fast (Type IIx) fibre is driven at high intensity, cross-bridge cycling consumes ATP at a rate that exceeds the maximum sustainable oxidative-phosphorylation flux. The cell makes up the difference by anaerobic glycolysis, which generates two net ATP per glucose plus lactate plus protons. The accumulation of protons (intracellular pH dropping from 7.0 to ~6.4 in maximal exercise), the depletion of phosphocreatine, the rise in inorganic phosphate, and the eventual fall in cytosolic ATP all directly inhibit cross-bridge cycling at multiple sites: low pH inhibits the actin-myosin ATPase, elevated Pi shifts the equilibrium toward the pre-power-stroke state, and reduced ATP slows the detachment step. The result is fatigue — defined as the inability to sustain target force. Type I fibres, with oxidative-phosphorylation capacity matched to a slower cross-bridge ATPase rate, can sustain force at submaximal levels almost indefinitely because their ATP supply tracks demand.

Athletic specialisation and the structural extrema. Elite sprinters' vastus lateralis biopsies show 60-70% Type II fibre composition and large cross-sectional areas in those Type II fibres; elite marathon runners' show 70-80% Type I composition with high mitochondrial density. These compositions are partly innate (heritability estimates around 50% from twin studies) and partly trained — the trained adaptations are addressed in the exercise-physiology sub-section below. The extremity is functional: a sprinter requires peak power for ~10 seconds and tolerates total exhaustion afterward; a marathoner requires submaximal power for hours and cannot afford even minor mitochondrial limitation. The trade-off is not a soft balance; it is a sharp Pareto frontier on the power-endurance axis, and elite athletes lie at the endpoints.

Recruitment ordering and fibre-type identity. The size principle, treated in detail in the next sub-section, ensures that Type I units are recruited before Type II units. This is not just an ordering quirk: it means that at low-intensity activity (postural maintenance, slow walking) only the Type I units fire, and their high oxidative capacity matches the low ATP demand of that activity. Type II units sit idle until ATP demand rises sharply, at which point they engage briefly and either recover during rest or push past their oxidative capacity into glycolytic fatigue. The system has co-evolved fibre-type composition, recruitment order, and metabolic pathway so that the supply-demand balance holds across the daily range of activity intensities.

Single-fibre and whole-muscle force-velocity spectra. A pure Type I fibre has a $v_{\max }$ around 1-2 fibre-lengths per second; pure Type IIx has $v_{\max }$ around 4-7 fibre-lengths per second. The corresponding Hill equation curvature parameters $a/F_0$ are around 0.25 for Type I (more curved, lower power) and 0.4 for Type II (less curved, higher peak power output). At the whole-muscle level, the force-velocity curve is a population-weighted superposition over fibre types, and shifts to the left (slower) or right (faster) as the recruited population changes with intensity. The whole-muscle peak mechanical power output is $W_{\max }\approx 0.1F_0{v}_{\max }$, reached at roughly one-third of $v_{\max }$ — this is the operating point most cyclic-locomotion muscles work near during steady-state activity.

Fibre-type plasticity and the limits of conversion. Chronic training shifts fibre-type composition along the slow-to-fast axis, but the IIa-IIx interconversion is much more accessible than the I-IIa interconversion. Endurance training reliably converts IIx → IIa (within weeks) and increases mitochondrial density across all fibre types; sprint training reliably converts IIa → IIx (within weeks) and increases sarcoplasmic reticulum density and glycolytic-enzyme activity. The Type I to Type IIa or Type IIa to Type I conversion is slower and limited in extent — months of training produce shifts on the order of 5-10% of fibre count, suggesting that the slow-fast identity is more deeply hard-wired than the within-fast subtype identity. Chronic low-frequency electrical stimulation, which mimics the firing pattern of slow motoneurons, can drive complete fast-to-slow conversion in animal studies, suggesting the molecular plasticity is present but normal-activity stimuli are too weak to access it fully.

Motor unit physiology and recruitment [Master]

A skeletal muscle does not contract as a single block. It contracts as an ensemble of motor units, each consisting of one alpha-motoneuron in the ventral horn of the spinal cord and the population of muscle fibres innervated by that motoneuron's branched axon. The motor unit is the indivisible quantum of motor output: when the motoneuron fires, all fibres in the unit contract together; when it falls silent, all fibres relax together.

Anatomy and numerics. Human muscles vary enormously in motor unit count and unit size. The first dorsal interosseous of the hand has roughly 100 motor units, each innervating ~100 fibres, with the smallest motor units innervating as few as 10-20 fibres — fine control is the physiological premium here. The medial gastrocnemius has ~600 motor units innervating an average of 1500-2000 fibres each. The gluteus maximus has ~1000+ motor units with averages above 2000 fibres per unit. The product (motor unit count) × (mean fibres per unit) gives total fibre count, on the order of $10^5$ to $10^6$ fibres for major muscles. Within a single motor unit all fibres are of the same fibre type — the motoneuron determines the fibre-type identity of its target fibres via its firing pattern and its trophic factors (a fact established by the cross-innervation experiments of Buller, Eccles, and Eccles in 1960, which showed that switching a fast and a slow motoneuron's targets switched the fibre-type identity of the targets within weeks).

The size principle (Henneman 1957). Henneman's Science 1957 paper and the more comprehensive J. Neurophysiol. 1965 papers articulated the central organising principle: motor units are recruited in an order determined by motoneuron size, from smallest to largest, regardless of the type of voluntary effort and largely regardless of which descending pathway drives the activation. The smallest motoneurons (smaller soma, smaller axon diameter, lower input resistance for a given specific membrane resistance) reach firing threshold first as synaptic drive increases; larger motoneurons reach threshold later. Because soma size correlates strongly with fibre-type (small motoneurons innervate Type I fibres, large motoneurons innervate Type IIx fibres), the size principle imposes a Type-I-first recruitment order. This order holds across muscle groups, across species, across reflex versus voluntary drives, and across slow versus fast contractions — it is one of the most robust facts in motor physiology.

The biophysical basis is direct. The input resistance of a motoneuron is inversely proportional to its surface area; for a given excitatory synaptic current, the smaller motoneuron experiences a larger voltage deflection and is more easily depolarised to threshold. The afterhyperpolarisation duration is also longer in small motoneurons (favouring sustained tonic firing) and shorter in large motoneurons (favouring brief phasic bursts), matching the slow versus fast contractile properties of the muscle fibres they innervate. The matching is not coincidence: it is a developmental match between motoneuron biophysics and target-fibre identity, mediated by activity-dependent trophic interaction.

Rate coding and force gradation. Once a motor unit is recruited, it can deliver more force by firing faster. A single twitch in a typical Type I unit lasts 100-150 ms; in Type II 30-50 ms. Between firings, the muscle relaxes partially. As firing rate climbs from the minimum sustained rate (around 6-8 Hz in humans) toward the tetanic rate (40-60 Hz for slow units, 80-120 Hz for fast units), successive twitches fuse and force rises through the unfused-tetanus regime toward the fused-tetanus plateau. Whole-muscle force during voluntary contraction is the sum of contributions from each active motor unit, with each unit's contribution depending on (i) whether it is recruited, (ii) its instantaneous firing rate, and (iii) the length-tension-velocity state of its fibres. The force decomposition $F(t)={\sum }_i{r}_i(t)\cdot f_i(L,v)$ where $r_i$ is the firing rate and $f_i$ is the per-unit force-length-velocity function captures this in a single equation.

The linear-summation envelope and the dynamic range. Across submaximal voluntary contractions, the relationship between recruitment and rate coding is muscle-dependent. In small distal muscles (intrinsic hand muscles) recruitment is essentially complete by ~50% of maximal voluntary contraction (MVC), and further force is generated by rate coding alone. In large proximal muscles (biceps, quadriceps) recruitment continues up to ~85% MVC, with rate coding playing a smaller role in dynamic range. The choice of strategy is functional: small muscles needing fine control rely on rate coding because rate coding has finer granularity (force changes smoothly with firing rate); large muscles needing high peak force rely on recruitment because recruitment is the only way to engage the high-force Type II units.

Twitch summation and the tetanic envelope, formally. The whole-muscle twitch response to a single impulse is approximated by a critically damped second-order linear response with rise time 20-100 ms and decay time 50-200 ms (fibre-type dependent). Under repeated impulses at rate $r$, the steady-state force is the convolution of the impulse train with the twitch kernel:

$$F_{ss}(r)=h\star \sum _k\delta (t-k/r)=r\cdot {\int }_0^{\infty }h(\tau )d\tau$$

in the limit where the impulse spacing $1/r$ is shorter than the kernel decay time. The integral ${\int }_0^{\infty }h(\tau )d\tau$ is the impulse-response area, and the steady-state force grows linearly with rate until the kernel decay becomes negligible (full fusion), at which point the steady-state force saturates at the tetanic value. Real muscle is more nonlinear (the kernel itself depends on previous activity through calcium accumulation), but the linear-summation picture is a useful first approximation across the operational range.

EMG: the experimental window. Surface and intramuscular electromyography (EMG) records the electrical activity of contracting motor units. A single motor unit action potential (MUAP) is a triphasic waveform whose amplitude depends on fibre count and electrode-fibre geometry. Decomposition of multi-unit EMG into single-MUAP trains, combined with force measurements, has confirmed Henneman's size principle in human voluntary contractions across many laboratories since the 1970s. Modern high-density surface EMG with blind-source separation can identify 20-30 individual motor units from a single recording, allowing direct experimental access to the rate-coding-recruitment decomposition. EMG amplitude (rectified and integrated) increases approximately linearly with force at low intensities and nonlinearly above 50% MVC because of cancellation of opposing-polarity action potentials in the volume-conduction signal; the nonlinearity is an artefact of recording, not of the underlying motor unit activity.

Reflex modulation. Motor unit recruitment is not driven solely by voluntary descending command. The Ia afferents from muscle spindles provide a monosynaptic excitatory drive to alpha-motoneurons innervating the same muscle (the stretch reflex), reinforcing the size principle by adding excitatory drive that preferentially recruits small motoneurons first. The Golgi tendon organ Ib afferents inhibit homonymous motoneurons during force production (autogenic inhibition), modulating tetanic firing rates and preventing dangerous loads. Renshaw cells in the ventral horn provide recurrent inhibition mediating reciprocal-inhibition control. The whole apparatus is a closed-loop control system that the nervous system uses to deliver smooth, graded force across the operational range; the muscle is the actuator, the motor unit is the quantum of actuation, the size principle is the recruitment rule, and rate coding is the gain modulation.

Exercise physiology and training adaptation [Master]

The skeletal muscle is the body's most plastic tissue. Mechanical load, neural drive pattern, hormonal milieu, and metabolic state all rewrite the fibre population and the molecular composition within fibres on timescales of weeks. The molecular bridge from system-level training stimulus to organ-level performance is built on three signalling axes — Akt/mTOR for hypertrophy, AMPK/PGC-1alpha for endurance adaptation, and satellite-cell biology for repair and growth — that constitute the modern foundation of exercise physiology.

Hypertrophy and the Akt/mTOR axis. Resistance training (high-load, low-repetition contractions) increases fibre cross-sectional area on the order of 20-40% over months of consistent training. The molecular trigger is mechanical: stretched and loaded fibres activate the phosphoinositide-3-kinase (PI3K)-Akt pathway, leading to phosphorylation and activation of mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). Bodine and colleagues showed in Nature Cell Biology 2001 that constitutively active Akt induces hypertrophy in mouse muscle and that rapamycin (mTORC1 inhibitor) blocks load-induced hypertrophy, definitively placing this axis as load-sensing-to-protein-synthesis. mTORC1 phosphorylates S6K1 and 4E-BP1, both of which act on the translational machinery: S6K1 enhances ribosome biogenesis and translation elongation, and 4E-BP1 phosphorylation releases eIF4E for cap-dependent translation initiation. The net effect is a 2-3-fold elevation in muscle protein synthesis rate during the 24-48 hours following a single bout of resistance exercise.

The opposing arm is protein degradation. The ubiquitin-proteasome system, regulated by the muscle-specific E3 ligases MuRF1 and atrogin-1 (MAFbx), tags myofibrillar proteins for degradation under conditions of unloading, disuse, or catabolic stress. Akt phosphorylates the FOXO transcription factors, sequestering them in the cytoplasm and preventing their nuclear induction of MuRF1 and atrogin-1 transcription. Hypertrophy thus involves a dual mechanism: Akt activation simultaneously increases protein synthesis (via mTOR) and decreases protein degradation (via FOXO suppression). Net protein accretion is the integral of synthesis minus degradation, and chronic training shifts both terms to favour accretion.

Hyperplasia: a small contribution at most. Whether resistance training increases fibre number (hyperplasia) or only fibre size (hypertrophy) was contested for decades. The consensus, after careful biopsy studies and modeling, is that the contribution of hyperplasia is small (well under 10% of cross-sectional area gain in trained humans) and most of the visible hypertrophy is single-fibre growth plus the addition of satellite-cell nuclei via fusion (so the volume of each nucleus's domain — its myonuclear domain — stays roughly constant). True myocyte addition does occur in extreme stretch-overload protocols in animal models and possibly contributes minimally in extreme human training, but the dominant mechanism in normal training is single-fibre hypertrophy with myonuclear accretion.

Satellite cell biology. Mauro 1961 first identified satellite cells as morphologically distinct cells lying between the sarcolemma and the basal lamina of mature muscle fibres. Decades of subsequent work established that satellite cells are the resident muscle stem cells, expressing the paired-box transcription factor Pax7 and existing in a normally quiescent state. On muscle injury, mechanical loading, or growth signals, satellite cells re-enter the cell cycle, proliferate as Pax7+/MyoD+ myoblasts, differentiate into myocytes, and fuse with each other (to form new fibres in regeneration) or with existing fibres (to add nuclei in hypertrophy). The Pax7 lineage tracing experiments of Lepper, Partridge, and Fan (2011 Development) and Murphy and colleagues (2011 Development) confirmed that satellite cells are necessary for regeneration after acute injury, settling a decades-long question of whether other progenitor populations could substitute.

For hypertrophy specifically, the satellite-cell contribution is dose-dependent on training intensity and protein synthesis demand. Modest hypertrophy can proceed via increased synthesis per existing nucleus, but extreme hypertrophy requires the addition of new nuclei via satellite-cell fusion to maintain the myonuclear domain at a roughly fixed cell-volume-per-nucleus ratio. This is the molecular substrate of the "muscle memory" phenomenon: previously trained muscle retains an elevated nuclear count from prior satellite-cell fusion even after detraining-induced atrophy, and re-training restores size more rapidly than initial training because the nuclei are already in place.

Endurance adaptation and the PGC-1alpha axis. Endurance training (low-load, high-repetition or sustained submaximal contractions) does not appreciably increase fibre size but profoundly remodels the metabolic and oxidative machinery within fibres. Mitochondrial volume density can double over 6-12 weeks of moderate endurance training, with proportional increases in capillary density (angiogenesis), oxidative-enzyme activity (citrate synthase, succinate dehydrogenase, cytochrome c oxidase), and substrate-handling capacity. The transcriptional master regulator is the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), identified by Spiegelman's lab in 1998 (Puigserver et al. Cell) as a brown-fat thermogenic coactivator and shown by Wu and colleagues in Cell 1999 to be the master regulator of mitochondrial biogenesis across tissues.

In skeletal muscle, PGC-1alpha is induced by exercise via multiple converging signals: AMPK activation (from elevated AMP ratio during exercise), p38 MAPK activation, calcium-calcineurin signalling (from elevated intracellular calcium during repeated contractions), and CaMKIV activation. Once expressed, PGC-1alpha coactivates nuclear respiratory factors (NRF-1, NRF-2), which transcribe nuclear-encoded mitochondrial genes including the mitochondrial transcription factor TFAM. TFAM then enters mitochondria and drives mitochondrial DNA replication and expression, completing the cascade from cytoplasmic exercise signal to expanded mitochondrial copy number. PGC-1alpha also coactivates the IIa MyHC promoter and the slow-fibre genetic program, driving the IIx-to-IIa fibre-type shift characteristic of endurance training.

The molecular bridge to organ-level performance. VO2max — the maximum rate of oxygen consumption during exhaustive exercise — is the canonical organism-level fitness measure and increases by 10-20% with consistent endurance training. The increase is multifactorial: cardiac stroke volume increases (organ-level cardiovascular adaptation, see 18.02.01); blood volume increases; capillary density in muscle increases; and most relevantly here, the mitochondrial density and oxidative capacity of trained muscle fibres rise. The fibre-level adaptation contributes the demand-side capacity — the muscle's ability to consume oxygen at high rate without metabolic acidosis — and the cardiovascular adaptation contributes the supply-side capacity — the rate of oxygen delivery from atmosphere to mitochondrial inner membrane. The total VO2max is set by the lower of the two and trained endurance athletes have rebalanced both terms.

Hormonal modulators of adaptation. Testosterone, growth hormone, IGF-1, insulin, cortisol, and thyroid hormones all modulate muscle adaptation. Testosterone enhances satellite-cell proliferation and protein synthesis, accelerating hypertrophy at supraphysiological doses (the basis of anabolic-steroid effects in athletes). IGF-1, both circulating and muscle-locally produced via mechanical signalling, activates the same PI3K-Akt-mTOR axis as direct mechanical loading. Cortisol elevates protein catabolism (via FOXO transcription factors and ubiquitin-ligase induction); chronic stress and overtraining elevate cortisol and antagonise hypertrophy. Thyroid hormone shifts fibre type toward Type II and increases overall metabolic rate. The full hormonal influence is treated in the 18.07.01 endocrine unit; here we observe that the molecular signalling within muscle integrates both local (mechanical) and systemic (hormonal) inputs into a unified anabolic-catabolic balance.

The interference effect. Concurrent resistance and endurance training produces less hypertrophy than resistance training alone, an observation called the "interference effect" (Hickson 1980). The molecular basis is that AMPK activation (the endurance-training sensor) directly inhibits mTORC1 via TSC2 phosphorylation, blunting the hypertrophy signal. The practical implication for athletes is that the order, timing, and balance of resistance and endurance training matters: separating them by ≥6-8 hours, or scheduling them on alternate days, minimises interference. The interference effect is a clean example of how molecular signalling sets the organ-level adaptation envelope.

Detraining kinetics. When training stops, the adaptations regress on a timescale set by the molecular half-life of the relevant machinery: capillary density decays within 2-3 weeks; mitochondrial density within 4-6 weeks; fibre size within 8-12 weeks; satellite-cell-derived nuclei persist much longer (months to years), supporting the muscle memory phenomenon. Detraining is not the inverse of training: the system has hysteresis, and retraining is faster than initial training because the persistent nuclei accelerate the protein-synthesis ramp-up.

Pathophysiology [Master]

Skeletal muscle diseases offer some of the cleanest examples in medicine of how loss of a single molecular component cascades to organ-level failure, and the therapeutic landscape illustrates the difficulty of restoring function to a tissue that is mechanically loaded, electrically driven, and metabolically demanding all at once.

Duchenne and Becker muscular dystrophy: dystrophin loss. Duchenne muscular dystrophy (DMD), the most common severe childhood muscle disease (affecting ~1 in 3500 male births), was the first muscular dystrophy whose gene product was identified — by Hoffman, Brown, and Kunkel in Cell 1987 — as the 427 kDa protein dystrophin encoded by the X-linked DMD gene. Dystrophin links the F-actin cytoskeleton at the sarcolemma to the extracellular matrix via the dystrophin-glycoprotein complex (DGC), which includes the dystroglycans, sarcoglycans, dystrobrevin, and syntrophin. The DGC is a mechanical anchor that distributes the lateral forces of contraction across the membrane and protects it from the shear stresses that would otherwise rupture lipid bilayers under repeated loading.

In DMD, frame-shifting mutations or large deletions in DMD abolish dystrophin expression entirely. The DGC disassembles. The sarcolemma loses its structural integrity. Each contraction induces small membrane tears, allowing extracellular calcium (millimolar in serum, micromolar in cytoplasm) to flood into fibres. Calcium activates calpain proteases, mitochondrial permeability transition, and inflammatory pathways; fibres undergo bouts of necrosis, attempt regeneration via satellite-cell fusion, and over years exhaust the satellite-cell pool and accumulate fibrosis and fatty infiltration. The clinical course is stereotyped: weakness from age 3-5, loss of ambulation around age 12, respiratory and cardiac failure in the third decade. Becker muscular dystrophy (BMD) is the milder allelic disorder arising from in-frame deletions that preserve a partially functional dystrophin protein; the natural history is correspondingly variable, with ambulation often preserved into adulthood.

Therapeutic landscape: corticosteroids (prednisone, deflazacort) extend ambulation by approximately 2-3 years through anti-inflammatory and mitochondrial-stabilising effects, but do not address the molecular defect. Exon-skipping antisense oligonucleotides (eteplirsen for exon 51 skipping, casimersen for exon 45 skipping, viltolarsen and golodirsen for exon 53) restore the reading frame around amenable mutations, producing internally-deleted dystrophin similar to BMD's. AAV-delivered micro-dystrophin gene therapy (delandistrogene moxeparvovec, approved 2023) delivers a shortened functional dystrophin construct. CRISPR-based exon excision is in early trials. Each approach restores partial function; none cures the disease, and the practical metric is rate of disease progression rather than functional reversal. The disease is the canonical example of a structural protein failure cascade and the canonical test case for muscle gene therapy.

Myasthenia gravis: receptor autoimmunity. Myasthenia gravis (MG) is an autoimmune disorder in which the patient produces autoantibodies against the postsynaptic acetylcholine receptor (AChR) at the neuromuscular junction (NMJ). Patrick and Lindstrom demonstrated in Science 1973 that immunisation of rabbits with purified Torpedo AChR produced a human-MG-like phenotype, establishing autoimmunity to AChR as the cause. The autoantibodies act through three converging mechanisms: complement-mediated lysis of the postsynaptic membrane (depleting AChR and disrupting junctional folds), accelerated internalisation of cross-linked receptors (reducing AChR density faster than synthesis can replace it), and direct receptor blockade. The net effect is a reduction in AChR density at the NMJ and a corresponding reduction in the safety factor for synaptic transmission.

The clinical signature is fatigable weakness: repeated activation of a muscle fails progressively as the marginal acetylcholine release becomes insufficient to depolarise the postsynaptic membrane to threshold against the reduced AChR density. Ocular muscles are usually affected first (ptosis, diplopia) because their NMJs have lower safety factors; bulbar muscles, respiratory muscles, and limb muscles follow as disease progresses. Severe disease can produce respiratory failure ("myasthenic crisis"). A subset of MG patients lack AChR antibodies but have antibodies against muscle-specific kinase (MuSK), a receptor-tyrosine kinase required for NMJ formation and stability; the clinical phenotype overlaps but with predilection for bulbar and respiratory involvement.

Therapeutic landscape: acetylcholinesterase inhibitors (pyridostigmine) raise the synaptic acetylcholine concentration and partially compensate for the reduced AChR density (symptomatic only). Immunosuppression (prednisone, azathioprine, mycophenolate) reduces autoantibody production. Plasmapheresis and intravenous immunoglobulin acutely remove or neutralise circulating antibodies in crisis. Thymectomy benefits seropositive MG patients (the thymus harbours antigen-presenting cells and B cells producing the relevant autoantibodies in many patients). Newer biologics include complement inhibitors (eculizumab, ravulizumab) and neonatal-Fc-receptor antagonists (efgartigimod, rozanolixizumab) that lower circulating IgG. The MG therapeutic story is the clinical mirror of the basic-science understanding of the NMJ — each layer of the synaptic transmission machinery has been targetable as understanding deepened.

Sarcopenia and aging. Sarcopenia is the age-related loss of muscle mass and function, defined operationally by the European Working Group on Sarcopenia in Older People (EWGSOP2, Age Ageing 2019) as low muscle strength plus low muscle quantity or quality, with severe sarcopenia adding low physical performance. Roughly 5-13% of community-dwelling 60-70-year-olds and 11-50% of those over 80 meet criteria, with corresponding increases in falls, fractures, hospitalisation, and mortality.

The mechanism is multifactorial. Motoneuron loss is the largest single contributor: from age 20 to 80, lumbar motor neuron counts decline by 25-50%, and the surviving motoneurons partially compensate by collateral reinnervation of denervated fibres. This produces enlarged motor units with mixed fibre types (the slow-firing surviving motoneuron imposes Type I identity on Type II fibres it now innervates), enlarged motor unit territories, and reduced fine-control resolution. EMG studies show motor unit number estimation declines steeply after age 60. Type II fibre atrophy is more prominent than Type I atrophy, partly because Type II motor units have larger soma and longer axons (more vulnerable to denervation) and partly because age-related declines in physical activity preferentially affect the high-intensity activities that recruit Type II units. The result is a shift in fibre-type composition toward Type I — useful for preservation of slow-twitch endurance but inadequate for power, balance, and rapid postural correction.

Further contributors: anabolic resistance (the same protein-feeding stimulus produces less protein synthesis in elderly than young muscle, partly via reduced Akt-mTOR signalling), mitochondrial dysfunction (reduced oxidative capacity, increased ROS production, mitochondrial DNA mutations accumulating with age), satellite-cell exhaustion (reduced pool size and reduced proliferative response to injury), chronic low-grade inflammation (elevated IL-6, TNF-alpha activating the FOXO catabolic pathway), and hormonal decline (lower testosterone, lower IGF-1, lower growth hormone). Each contributes a fraction of the phenotype, and the contributions interact — denervated fibres are also more susceptible to atrophy, anabolic resistance amplifies the effect of disuse, satellite-cell exhaustion blocks repair from minor injuries.

Therapeutic landscape: resistance training is the most effective intervention by a wide margin, producing 10-30% strength gains in elderly populations even when initiated at age 80+ and partially reversing the molecular changes (improved Akt-mTOR signalling, modest mitochondrial biogenesis, satellite-cell proliferation in response to load). Adequate protein intake (1.0-1.2 g/kg/day in healthy elderly, 1.2-1.5 g/kg/day during training or illness, leucine-rich sources) supports the protein-synthetic capacity. Vitamin D sufficiency supports neuromuscular function. Pharmacological agents in trials include myostatin inhibitors (bimagrumab, landogrozumab — efficacy mixed), selective androgen receptor modulators (SARMs), and ghrelin receptor agonists; none has yet entered routine clinical use for sarcopenia. The therapeutic centrepiece remains the load-driven activation of the same adaptive pathways treated in the exercise-physiology sub-section above.

Other muscle pathology in brief. Inflammatory myopathies (polymyositis, dermatomyositis, inclusion-body myositis) are autoimmune disorders of the muscle fibre itself; metabolic myopathies (McArdle disease — myophosphorylase deficiency, Pompe disease — acid alpha-glucosidase deficiency, mitochondrial myopathies) reflect failures of energy supply with phenotypes ranging from exercise intolerance to severe systemic disease; channelopathies (myotonia congenita, periodic paralyses, malignant hyperthermia) reflect defects in the ion channels controlling excitability and excitation-contraction coupling. The disease panel reads the entire physiology of the unit: structural (dystrophinopathies), synaptic (myasthenia), neural (motoneuron disease), regenerative (satellite-cell disorders), and metabolic (storage myopathies) failures all reach clinical attention because the muscle integrates them into the single phenotype of weakness, fatigue, or disordered movement. The diagnostic logic of clinical neuromuscular medicine is, in effect, an inverse problem on the physiology developed in this unit.

Synthesis. Skeletal muscle physiology builds toward 18.04.02 pending cross-bridge biophysics by providing the system-level context in which actin-myosin cycling is recruited, modulated, fueled, and integrated into organ-level performance. The foundational reason that fibre-type heterogeneity exists is the ATP supply-demand trade-off: a single fibre cannot be simultaneously fast and efficient because mitochondrial volume and ATPase rate impose competing optima. This is exactly the regime in which the size principle of [Henneman 1957] does its work — recruitment-ordered by motoneuron size, it identifies small motor units with Type I fibres and large motor units with Type II fibres, so the slow-fast metabolic-mechanical spectrum maps directly to the recruitment-order axis. Putting these together with the exercise-physiology bridge of Akt-mTOR-PGC-1alpha signalling, the central insight is that mechanical load and neural drive together rewrite the muscle's molecular composition on a timescale of weeks, producing adaptations that change both supply (mitochondria, capillaries) and demand (fibre size, ATPase rate). The bridge from molecular signalling to organ-level performance is the same bridge that pathophysiology breaks: dystrophin loss identifies structural-protein failure with mechanical-stress-driven necrosis; myasthenia gravis identifies receptor autoimmunity with safety-factor collapse; sarcopenia identifies motoneuron loss with fibre-type homogenisation. The pattern recurs across every muscle pathology — a molecular failure cascades through the same physiology by which normal training writes the body's most plastic tissue, and the therapeutic landscape generalises the molecular substrate that exercise physiology and pathophysiology share.

Connections [Master]

• Cross-bridge biophysics and the actin-myosin cycle 18.04.02 pending. The molecular substrate of contraction — sliding-filament theory, the Lymn-Taylor cycle, single-molecule mechanics, the Huxley 1957 rate-distortion model — lives in the sibling unit. The present unit treats the integration of millions of cross-bridges across motor units, fibre types, neural drive patterns, and adaptive states; 18.04.02 pending treats one cross-bridge cycle. The relationship is the canonical molecular-to-organ-system reduction.

• Glycolysis and the citric-acid cycle 17.04.01. Anaerobic glycolysis is the dominant ATP supply for fast (Type IIx) fibres during high-intensity activity. The accumulation of lactate and protons that fatigues these fibres is set by glycolytic flux exceeding mitochondrial-pyruvate-handling capacity; the chemistry of the pathway lives in the cell-biology unit and is read here as the supply-side ceiling for fast-fibre power.

• Oxidative phosphorylation 17.04.02 pending. Aerobic ATP supply via mitochondrial electron transport and ATP synthase is the dominant ATP source for slow (Type I) fibres and for sustained exercise across all fibre types. The PGC-1alpha-driven mitochondrial biogenesis adaptation to endurance training expands this supply-side capacity, and is the molecular mechanism behind the VO2max increases of training. The mitochondrial chemistry lives in the cell-biology unit.

• Action potentials and neuromuscular junction 17.09.01. The action potential along the motoneuron axon, the calcium-triggered acetylcholine release at the neuromuscular junction, and the postsynaptic depolarisation initiate every contraction. Excitation-contraction coupling treated at intermediate tier here builds on this neural-input substrate. Myasthenia gravis disrupts this layer specifically and confirms its load-bearing role in muscle function.

• Endocrine hormones 18.07.01. Testosterone, growth hormone, IGF-1, insulin, cortisol, and thyroid hormones modulate muscle protein synthesis, satellite-cell activity, fibre-type identity, and metabolic state. The exercise-physiology sub-section above identifies the within-muscle signalling pathways (Akt-mTOR, FOXO) that integrate hormonal inputs with mechanical inputs into a unified anabolic-catabolic balance.

• Cardiovascular physiology 18.02.01. Oxygen and substrate delivery to working muscle and removal of metabolic by-products require coordinated cardiovascular response. Stroke volume, cardiac output, peripheral vasodilation, and capillary recruitment all increase with exercise intensity; the VO2max ceiling combines this supply-side adaptation with the muscle-side oxidative capacity treated in the exercise-physiology sub-section. The cardiovascular unit treats the supply side; this unit treats the demand side.

• Cardiac pacemaker and conduction 18.02.02. Cardiac muscle shares the actin-myosin substrate with skeletal muscle and exhibits a parallel but distinct excitation-contraction coupling (calcium-induced calcium release rather than mechanical DHPR-RyR1 coupling). The cardiac unit identifies the calcium-channel and pacemaker physiology of heart muscle; the contrast with skeletal muscle clarifies what is conserved (actin-myosin core, fibre-type-equivalent ventricular regional specialisation) and what is specific (calcium-handling, length-dependent activation, no voluntary control).

• Nervous system gross anatomy 18.05.01 pending. Motor control descends from primary motor cortex through pyramidal and extrapyramidal pathways to the spinal alpha-motoneuron, which is the final common path to skeletal muscle. The motor-unit recruitment described in the motor-unit sub-section above is the output stage of this control hierarchy. Stretch reflex, Golgi tendon organ reflex, and recurrent inhibition operate within the spinal cord and modulate motoneuron firing locally.

Historical & philosophical context [Master]

Skeletal muscle physiology as an integrative discipline grew from three separate research programmes in the early 20th century, fused in the 1950s-1970s into the modern synthesis. Whole-muscle mechanics were the subject of A. V. Hill's work — Hill 1922 received the Nobel Prize for heat measurements in tetanised muscle, leading to the 1938 hyperbolic force-velocity relation ^{[Hill 1938]} that remains the textbook constitutive law of muscle and the empirical relation that the molecular cross-bridge model was eventually required to explain. Motor control was the subject of Sherrington's school (Sherrington 1906 Integrative Action of the Nervous System) and later Eccles's school, which established the reflex architecture of the spinal cord and the synaptic mechanism of the neuromuscular junction (Eccles, Hodgkin, and Huxley shared the 1963 Nobel Prize for the action-potential mechanism). Fibre-type biology was opened by histochemical methods of the 1950s-60s (Engel 1962 myosin ATPase histochemistry) and extended through the 1970s and 1980s as MyHC isoform analysis matured.

The synthesis is articulated cleanly by Henneman's 1957 Science paper ^{[Henneman 1957]} and the follow-up J. Neurophysiol. 1965 papers ^{[Henneman 1965]}. Henneman demonstrated experimentally in cat triceps surae that motoneuron size determined recruitment order, that the order was preserved across diverse activation conditions, and that the size axis mapped onto the fibre-type axis. The size principle is now the central organising principle of motor physiology because it identifies a single biophysical parameter (motoneuron size) with a multi-level functional ordering (recruitment threshold, fibre-type identity, metabolic phenotype, fatigue resistance). Buller, Eccles, and Eccles (1960) added the cross-innervation evidence that motoneurons impose fibre-type identity on their targets, making the size-fibre-type correspondence developmental rather than merely correlative.

Modern molecular exercise physiology dates from the 1990s. The PGC-1alpha pathway was identified by Spiegelman's group in 1998 (Puigserver et al. Cell 92) and within years was placed as the master regulator of mitochondrial biogenesis (Wu et al. 1999 Cell 98 ^{[Wu 1999]}). The Akt-mTOR axis as the load-induced hypertrophy pathway was established by Bodine et al. 2001 Nature Cell Biology ^{[Bodine 2001]} and refined through the next two decades by Sandri, Glass, and many others. The integration of these molecular pathways with the older organ-system framework was completed in the 2000s and 2010s; Schiaffino and Reggiani's 2011 Physiol. Rev. synthesis ^{[Schiaffino Reggiani 2011]} is the canonical modern reference.

Pathophysiology has its own historical arc. Duchenne described the eponymous dystrophy clinically in the 1860s; the DMD gene was positionally cloned by Kunkel's lab and the protein identified as dystrophin in Hoffman, Brown, and Kunkel 1987 Cell ^{[Hoffman 1987]}, opening the molecular era of muscular dystrophy research. Myasthenia gravis was clinically delineated by Walker in 1934 (treating with physostigmine, presaging modern acetylcholinesterase inhibitor therapy); the autoimmune mechanism was established by Patrick and Lindstrom 1973 Science ^{[Patrick Lindstrom 1973]}. Sarcopenia was named by Irwin Rosenberg in 1989 and given its modern operational definition by the EWGSOP2 Age Ageing 2019 consensus ^{[EWGSOP2 2019]}.

Mauro's 1961 identification of satellite cells ^{[Mauro 1961]} opened muscle stem-cell biology; the field matured through Pax7-lineage tracing in the 2000s and is now integrated into the exercise-physiology and regeneration narratives. The convergence of fibre-type plasticity, satellite-cell biology, and molecular signalling into a single integrative framework is one of the major achievements of late-20th-century physiology, and remains an active frontier as the molecular and cellular layers continue to deepen.

Bibliography [Master]

@article{Hill1938,
  author = {Hill, A. V.},
  title = {The heat of shortening and the dynamic constants of muscle},
  journal = {Proc. Roy. Soc. London Ser. B},
  volume = {126},
  year = {1938},
  pages = {136--195},
}

@article{Henneman1957,
  author = {Henneman, Elwood},
  title = {Relation between size of neurons and their susceptibility to discharge},
  journal = {Science},
  volume = {126},
  year = {1957},
  pages = {1345--1347},
}

@article{HennemanSomjenCarpenter1965,
  author = {Henneman, Elwood and Somjen, George and Carpenter, David O.},
  title = {Functional significance of cell size in spinal motoneurons},
  journal = {J. Neurophysiol.},
  volume = {28},
  year = {1965},
  pages = {560--580},
}

@article{Mauro1961,
  author = {Mauro, Alexander},
  title = {Satellite cell of skeletal muscle fibers},
  journal = {J. Biophys. Biochem. Cytol.},
  volume = {9},
  year = {1961},
  pages = {493--495},
}

@article{Hoffman1987,
  author = {Hoffman, Eric P. and Brown, Robert H. and Kunkel, Louis M.},
  title = {Dystrophin: the protein product of the {Duchenne} muscular dystrophy locus},
  journal = {Cell},
  volume = {51},
  year = {1987},
  pages = {919--928},
}

@article{PatrickLindstrom1973,
  author = {Patrick, Jim and Lindstrom, Jon},
  title = {Autoimmune response to acetylcholine receptor},
  journal = {Science},
  volume = {180},
  year = {1973},
  pages = {871--872},
}

@article{Bodine2001,
  author = {Bodine, Sue C. and others},
  title = {{Akt/mTOR} pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo},
  journal = {Nature Cell Biology},
  volume = {3},
  year = {2001},
  pages = {1014--1019},
}

@article{Wu1999,
  author = {Wu, Zhidan and Puigserver, Pere and Andersson, Ulf and Zhang, Chenyu and Adelmant, Guillaume and Mootha, Vamsi and Troy, Amy and Cinti, Saverio and Lowell, Bradford and Scarpulla, Richard C. and Spiegelman, Bruce M.},
  title = {Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator {PGC-1}},
  journal = {Cell},
  volume = {98},
  year = {1999},
  pages = {115--124},
}

@article{SchiaffinoReggiani2011,
  author = {Schiaffino, Stefano and Reggiani, Carlo},
  title = {Fiber types in mammalian skeletal muscles},
  journal = {Physiol. Rev.},
  volume = {91},
  year = {2011},
  pages = {1447--1531},
}

@article{GordonHuxleyJulian1966,
  author = {Gordon, A. M. and Huxley, A. F. and Julian, F. J.},
  title = {The variation in isometric tension with sarcomere length in vertebrate muscle fibres},
  journal = {J. Physiol.},
  volume = {184},
  year = {1966},
  pages = {170--192},
}

@article{EWGSOP2_2019,
  author = {Cruz-Jentoft, Alfonso J. and others},
  title = {Sarcopenia: revised {European} consensus on definition and diagnosis},
  journal = {Age Ageing},
  volume = {48},
  year = {2019},
  pages = {16--31},
}

@book{McMahon1984,
  author = {McMahon, Thomas A.},
  title = {Muscles, Reflexes, and Locomotion},
  publisher = {Princeton University Press},
  year = {1984},
}

@book{BoronBoulpaep2017,
  author = {Boron, Walter F. and Boulpaep, Emile L.},
  title = {Medical Physiology},
  edition = {3},
  publisher = {Elsevier},
  year = {2017},
}

@book{Enoka2015,
  author = {Enoka, Roger M.},
  title = {Neuromechanics of Human Movement},
  edition = {5},
  publisher = {Human Kinetics},
  year = {2015},
}